Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital
5.4.22
NovaQuest in the News
FDA Approves Mycovia Pharmaceuticals’ VIVJOA™ (oteseconazole), the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)
4.28.22
Grünenthal and NovaQuest enter agreement to advance the resiniferatoxin global Phase III program in osteoarthritis
3.29.22
